SCI Pharmtech Inc
TWSE:4119
Net Margin
SCI Pharmtech Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| TW |
S
|
SCI Pharmtech Inc
TWSE:4119
|
8.1B TWD |
33%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
776.5B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
377.9B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.3T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
214.5B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.4B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
170.3B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
205.6B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
139.5B USD |
13%
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on SCI Pharmtech Inc's most recent financial statements, the company has Net Margin of 33.2%.
You don't have any saved screeners yet